{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T05:45:15Z","timestamp":1741067115998,"version":"3.38.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004895","name":"European Social Fund Plus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005884","name":"Spanish National Cardiovascular Research Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005884","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM21\/00206"],"award-info":[{"award-number":["CM21\/00206"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jclinepi.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Epidemiology"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jclinepi.2024.111621","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T06:04:24Z","timestamp":1733292264000},"page":"111621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Determinants of cost-effectiveness results of biological therapies for severe asthma: a systematic methodological assessment"],"prefix":"10.1016","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0611-735X","authenticated-orcid":false,"given":"Laura de la","family":"Torre-P\u00e9rez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5371-0979","authenticated-orcid":false,"given":"Marilina","family":"Santero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-1520","authenticated-orcid":false,"given":"Wendy","family":"Nieto-Gutierrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5026-9724","authenticated-orcid":false,"given":"Christine","family":"Giesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Nardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6958-0275","authenticated-orcid":false,"given":"Claudia","family":"Cosma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro Silva","family":"Pires","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1278-7053","authenticated-orcid":false,"given":"Andrea","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4145-0944","authenticated-orcid":false,"given":"Marcello","family":"Simonini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0799-3303","authenticated-orcid":false,"given":"Camila Quirland","family":"Lazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3454-6266","authenticated-orcid":false,"given":"Feng","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-8504","authenticated-orcid":false,"given":"Pablo","family":"Alonso-Coello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2016","series-title":"Cost\u2013effectiveness analysis","author":"Thomas","key":"10.1016\/j.jclinepi.2024.111621_bib1"},{"key":"10.1016\/j.jclinepi.2024.111621_bib2","doi-asserted-by":"crossref","first-page":"E639","DOI":"10.1001\/amajethics.2021.639","article-title":"How does cost-effectiveness analysis inform health care decisions?","volume":"23","author":"Kim","year":"2021","journal-title":"AMA J Ethics"},{"key":"10.1016\/j.jclinepi.2024.111621_bib3","article-title":"Industry sponsorship bias in cost effectiveness analysis: registry based analysis","volume":"377","author":"Xie","year":"2022","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111621_bib4","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1001\/jama.282.15.1453","article-title":"Evaluation of conflict of interest in economic analyses of new drugs used in oncology","volume":"282","author":"Friedberg","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jclinepi.2024.111621_bib5","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/0885066603255683","article-title":"Industry-sponsored economic studies in critical and intensive care versus studies sponsored by nonprofit organizations","volume":"18","author":"Hartmann","year":"2003","journal-title":"J Intensive Care Med"},{"key":"10.1016\/j.jclinepi.2024.111621_bib6","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1192\/03-2","article-title":"Quantitative analysis of sponsorship bias in economic studies of antidepressants","volume":"183","author":"Baker","year":"2003","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.jclinepi.2024.111621_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0069462","article-title":"When are statins cost-effective in cardiovascular prevention? A systematic review of sponsorship bias and conclusions in economic evaluations of statins","volume":"8","author":"Catal\u00e1-L\u00f3pez","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jclinepi.2024.111621_bib8","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1177\/0272989X18776636","article-title":"Sponsorship bias in base-case values and uncertainty bounds of health economic evaluations? A systematic review of herpes zoster vaccination","volume":"38","author":"Bilcke","year":"2018","journal-title":"Med Decis Making"},{"key":"10.1016\/j.jclinepi.2024.111621_bib9","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1001\/jamaoncol.2015.3928","article-title":"Associations between industry sponsorship and results of cost-effectiveness analyses of drugs used in breast cancer treatment","volume":"2","author":"Lane","year":"2016","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jclinepi.2024.111621_bib10","first-page":"MR000033","article-title":"Industry sponsorship and research outcome","volume":"2","author":"Lundh","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jclinepi.2024.111621_bib11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1017\/S0266462308080343","article-title":"Key principles for the improved conduct of health technology assessments for resource allocation decisions","volume":"24","author":"Drummond","year":"2008","journal-title":"Int J Technol Assess Health Care"},{"author":"Ryder","key":"10.1016\/j.jclinepi.2024.111621_bib12"},{"author":"Jacobs","key":"10.1016\/j.jclinepi.2024.111621_bib13"},{"key":"10.1016\/j.jclinepi.2024.111621_bib14","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/14737167.2017.1331432","article-title":"The influence of time horizon on results of cost-effectiveness analyses","volume":"17","author":"Kim","year":"2017","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jclinepi.2024.111621_bib16","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/reep\/reu008","article-title":"Should governments use a declining discount rate in project analysis?","volume":"8","author":"Arrow","year":"2014","journal-title":"Rev Environ Econ Pol"},{"key":"10.1016\/j.jclinepi.2024.111621_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1017\/S0266462305050324","article-title":"Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria","volume":"21","author":"Evers","year":"2005","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.jclinepi.2024.111621_bib18","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4172\/2155-6156.1000438","article-title":"Dirk. Cost-effectiveness of therapeutic education to prevent the development and progression of type 2 diabetes: systematic review","volume":"5","author":"Odnoletkova","year":"2014","journal-title":"J Diabetes Metab"},{"key":"10.1016\/j.jclinepi.2024.111621_bib19","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1136\/bmj.38737.607558.80","article-title":"Bias in published cost effectiveness studies: systematic review","volume":"332","author":"Bell","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jclinepi.2024.111621_bib20","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14737167.2023.2221435","article-title":"Economic evaluation of biological treatments in patients with severe asthma: a systematic review","volume":"23","author":"Alves","year":"2023","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.jclinepi.2024.111621_bib21","doi-asserted-by":"crossref","first-page":"262","DOI":"10.12701\/yujm.2020.00647","article-title":"Biological treatments for severe asthma","volume":"37","author":"Jin","year":"2020","journal-title":"Yeungnam Univ J Med"},{"key":"10.1016\/j.jclinepi.2024.111621_bib22","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jclinepi.2024.111621_bib23","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1007\/s40273-018-0658-x","article-title":"Cost-effectiveness of biological asthma treatments: a systematic review and recommendations for future economic evaluations","volume":"36","author":"McQueen","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jclinepi.2024.111621_bib24","series-title":"Cochrane Handbook for Systematic Reviews of Interventions","article-title":"Chapter 20: economic evidence","author":"Aluko","year":"2024"},{"key":"10.1016\/j.jclinepi.2024.111621_bib25","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"author":"de la Torre-P\u00e9rez","key":"10.1016\/j.jclinepi.2024.111621_bib26"},{"year":"2014","series-title":"Users\u2019 Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice","author":"Guyatt","key":"10.1016\/j.jclinepi.2024.111621_bib27"},{"author":"Shanaa","key":"10.1016\/j.jclinepi.2024.111621_bib28"},{"key":"10.1016\/j.jclinepi.2024.111621_bib31","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s40273-019-00825-1","article-title":"The challenge of transparency and validation in health economic decision modelling: a view from mount hood","volume":"37","author":"Kent","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jclinepi.2024.111621_bib32","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40273-019-00842-0","article-title":"Transparency in health economic modeling: options, issues and potential solutions","volume":"37","author":"Wu","year":"2019","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jclinepi.2024.111621_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.jval.2019.03.003","article-title":"A new method to determine the optimal willingness to pay in cost-effectiveness analysis","volume":"22","author":"Phelps","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jclinepi.2024.111621_bib34","first-page":"2159","article-title":"Economic evaluation of health interventions: a critical review","volume":"51","author":"Mosadeghrad","year":"2022","journal-title":"Iran J Public Health"},{"key":"10.1016\/j.jclinepi.2024.111621_bib35","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2471\/BLT.15.164418","article-title":"Cost-effectiveness thresholds: pros and cons","volume":"94","author":"Bertram","year":"2016","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.jclinepi.2024.111621_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vhri.2019.09.009","article-title":"Is there something else beyond cost-effectiveness analysis for public health decision making?","volume":"23","author":"Casta\u00f1eda-Orjuela","year":"2020","journal-title":"Value Health Reg Issues"},{"key":"10.1016\/j.jclinepi.2024.111621_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5334\/ijic.4675","article-title":"Methodological quality of economic evaluations in integrated care: evidence from a systematic review","volume":"19","author":"Kadu","year":"2019","journal-title":"Int J Integr Care"},{"key":"10.1016\/j.jclinepi.2024.111621_bib38","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jval.2018.10.006","article-title":"Use of checklists in reviews of health economic evaluations, 2010 to 2018","volume":"22","author":"Watts","year":"2019","journal-title":"Value Health"},{"key":"10.1016\/j.jclinepi.2024.111621_bib40","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-010-0870-7","article-title":"Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review","volume":"121","author":"Jang","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jclinepi.2024.111621_bib41","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.35123","article-title":"Characteristics of cost-effectiveness studies for oncology drugs approved in the United States from 2015-2020","volume":"4","author":"Haslam","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jclinepi.2024.111621_bib42","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1016\/j.jacc.2008.09.018","article-title":"Interpreting the results of cost-effectiveness studies","volume":"52","author":"Cohen","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jclinepi.2024.111621_bib43","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13561-023-00446-7","article-title":"Global trends in the scientific research of the health economics: a bibliometric analysis from 1975 to 2022","volume":"13","author":"Barbu","year":"2023","journal-title":"Health Econ Rev"}],"container-title":["Journal of Clinical Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624003779?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0895435624003779?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T15:32:38Z","timestamp":1741015958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0895435624003779"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":39,"alternative-id":["S0895435624003779"],"URL":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111621","relation":{},"ISSN":["0895-4356"],"issn-type":[{"type":"print","value":"0895-4356"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Determinants of cost-effectiveness results of biological therapies for severe asthma: a systematic methodological assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jclinepi.2024.111621","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111621"}}